CareDx, Inc. $CDNA Shares Acquired by Meeder Asset Management Inc.

Meeder Asset Management Inc. lifted its holdings in CareDx, Inc. (NASDAQ:CDNA – Free Report) by 2,721.2% in the 3rd quarter, Holdings Channel reports. The firm owned 23,416 shares of the company’s stock after acquiring an additional 22,586 shares during the period. Meeder Asset Management Inc.’s holdings in CareDx were worth $1,522,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of CareDx during the second quarter valued at $137,219,000. Bamco Inc. NY purchased a new stake in shares of CareDx during the second quarter valued at $55,214,000. Dimensional Fund Advisors LP boosted its position in shares of CareDx by 11.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company’s stock valued at $25,375,000 after buying an additional 151,934 shares during the last quarter. Renaissance Technologies LLC increased its holdings in CareDx by 7.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,184,398 shares of the company’s stock worth $20,561,000 after buying an additional 79,200 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in CareDx in the 2nd quarter worth about $16,297,000.

CareDx Price Performance

NASDAQ CDNA opened at $71.92 on Friday. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 112.79 and a beta of 2.51. CareDx, Inc. has a 1-year low of $15.56 and a 1-year high of $90.87. The business’s fifty day moving average price is $68.21 and its 200-day moving average price is $37.76.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.25 by $0.45. The company had revenue of $139.36 million during the quarter, compared to analyst estimates of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. CareDx’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 earnings per share. Equities research analysts anticipate that CareDx, Inc. will post 1.00 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on CDNA. Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Monday, August 3rd. Zacks Research raised shares of CareDx from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 5th. Wall Street Zen downgraded shares of CareDx from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. BTIG Research lifted their price target on shares of CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, HC Wainwright reissued a “neutral” rating and set a $46.00 price objective on shares of CareDx in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.33.

Check Out Our Latest Research Report on CDNA

Insider Buying and Selling at CareDx

In other CareDx news, Director Richard Bryan Riggsbee sold 5,285 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $74.77, for a total transaction of $395,159.45. Following the completion of the sale, the director directly owned 34,027 shares in the company, valued at $2,544,198.79. The trade was a 13.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Keith Kennedy sold 61,961 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $77.82, for a total transaction of $4,821,805.02. Following the sale, the chief financial officer directly owned 199,147 shares of the company’s stock, valued at $15,497,619.54. The trade was a 23.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 83,143 shares of company stock valued at $6,475,506. 2.40% of the stock is owned by company insiders.

About CareDx

(Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Featured Articles

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA – Free Report).

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.